Anaplastic lymphoma kinase (ALK) is an important drug target in many cancers, including lymphoma, neuroblastoma and lung cancer. Here, we demonstrate proof-ofprinciple for a novel and inexpensive assay for ALK inhibitor activity and identification in zebrafish. We demonstrate that the human oncogenic ALK fusion, NPM-ALK, drives overproduction of iridophores, a highly visible, shiny pigment cell-type in zebrafish.
Introduction
Receptor tyrosine kinases (RTKs) are a large family of transmembrane receptor proteins with widespread functions in embryonic development (1) . They usually function by ligand-induced dimerization, resulting in trans-phosphorylation of the intracellular kinase domain, and generating docking sites for various adaptor proteins triggering multiple intracellular signalling cascades. Elevated RTK activity is a common cause of human disease, so that effective RTK inhibitor compounds are in great demand as therapeutic agents (2) .
Anaplastic lymphoma kinase (ALK) is an RTK, first identified in human anaplastic large cell lymphoma (ALCL (3)), but subsequently shown to be a key driver in a subset of cancers, including neuroblastoma, non-small cell lung cancer (NSCLC), and inflammatory myofibroblastic tumours (IMT) (4) (5) (6) (7) (8) . In all cases, disease is associated with elevated ALK signalling, due either to gene amplification or activating mutations. In neuroblastoma, activating point mutations (e.g. F1174L) are most common (5, 7, 9, 10) . In ALCL, IMT and NSCLC, constitutive kinase signalling usually results from translocation events generating abnormal fusion proteins (11) , such as the frequent t(2,5)(p23;q35) translocation resulting in expression of a nucleophosmin (NPM)-ALK fusion protein (3) .
Validation of ALK as an important therapeutic target has led to the development of ALK inhibitors, including both the clinically-approved drug Crizotinib (PF-2341066) [1] and TAE684 [2] (Figure 1) , shown to be effective in various in vitro and in vivo preclinical and clinical models (12, 13, 14, 15) . However, Crizotinib resistance is already being seen clinically, in one patient resulting from the acquisition of the F1174L mutation in the kinase domain (15) , underlining the need for novel assays to develop ALK inhibitors working through different modalities.
Zebrafish have become a valuable research platform for drug discovery and development because of the ease of detection of drug efficacy in intact embryos.
Previously, we have shown that loss-of-function alleles for leukocyte tyrosine kinase (Ltk), the sister kinase to ALK, lack iridophores in zebrafish (16) . Iridophores are neural crest-derived pigment cells that are clearly visible as shiny silver cells in the developing zebrafish embryo. Zebrafish ltk is expressed in the neural crest cells, and acts cellautonomously to drive fate-specification of iridophores; ltk mutants lack iridophores due to a failure of this iridophore fate specification process, but show otherwise normal body morphology (16) . Noting the structural similarity between the LTK and ALK kinase domains, we reasoned that constitutively activated ALK variants might be able to substitute for Ltk function if they were expressed in the zebrafish neural crest. If so, we then would be able to test the functional activity of human ALK cancer mutations as well as their sensitivity to small molecule inhibition in the zebrafish system by using iridophore numbers as a straight-forward phenotypic read-out of ALK activity. Here we report that expression of the human oncogenic ALK fusion, NPM-ALK, in zebrafish neural crest restores iridophore development in ltk mutant embryos, and can also promote ectopic and supernumerary iridophores in wild-type embryos. In addition, we used the small molecule ALK inhibitor, TAE684 (13) , to provide proof-of-principle evidence that loss of NPM-ALK-dependent iridophores can be used as a simple, in vivo assay for ALK inhibition. We also observed TAE684-dependent phenocopying of the ltk mutant phenotype, and show that this compound also shows inhibitory activity against Ltk, consistent with kinome-wide selectivity profiling data. Furthermore, at higher doses of TAE684 non-specific effects including shortened body axis and embryonic lethality become apparent. Likewise, we show that Crizotinib treatment also inhibits ALKdependent iridophores in our zebrafish assay. Treatment with a MEK inhibitor also decreased iridophore numbers and sensitized the response to Crizotinib, suggesting that MEK signaling lies downstream of ALK/Ltk signaling in iridophore specification.
Our studies identify powerful new in vivo assays for ALK and LTK inhibitor screening.
Results and Discussion
Human NPM-ALK expression can rescue loss of Ltk signaling in zebrafish. In zebrafish, iridophores are prominent shiny cells that cover the eyes, and form a series of spots above the brain and above and below the trunk and tail segmental muscle blocks (Figure 2b) . We have shown that ltk mutants form an allelic series, with the strongest alleles (e.g. ltk ty82 ; Figure 2d , h) resulting in embryos showing no iridophores, whereas mutants for intermediate alleles have only reduced iridophore numbers; in all other respects embryos are morphologically normal, except that the swim bladder fails to inflate (16) . Similarly, morpholino knockdown of Ltk in wild-type embryos gave good phenocopies of the ltk mutant phenotypes (16) . In ltk ty82 mutants (hereafter referred to as ltk mutants) a premature stop codon results in a predicted protein that is truncated and completely lacks the tyrosine kinase domain. ALK is 64% identical at the amino acid level to LTK (17) . We tested whether the human oncogenic ALK variant, NPM-ALK, which has constitutively active kinase signaling (18, 19) , would rescue the ltk phenotype (Figure 2a ). We generated an expression construct, psox10:NPM-ALK, encoding the NPM-ALK fusion under the control of the sox10 promoter shown to drive expression in neural crest (20) . Injection of this construct into 1-cell stage ltk mutants resulted in prominent rescue of iridophores compared with uninjected siblings (Figure   2d ,e). At the doses used in these initial studies, we also saw substantial early embryonic lethality, but nevertheless rescue was observed in c. 25% of surviving mutant embryos, consistent with the expected highly mosaic distribution of the injected plasmid DNA and with the strictly localized expression of the sox10 promoter. Rescued iridophores tend to form striking clusters in a position dorsal to the neural tube (Figure   2e ). Furthermore, injected wild-type sibling embryos often showed supernumerary and/or ectopic iridophores in addition to the normal complement of (ltk-dependent) iridophores (Figure 2b,c) .
We also tested an analogous construct, psox10:NPM-Ltk, in which the ALK coding region from the NPM-ALK construct was substituted with the equivalent region of zebrafish Ltk. Again, injection of this construct rescued iridophore development in a proportion of ltk mutant embryos, and generated supernumerary and/or ectopic cells in wild-type siblings (Figure 2f-i) . We note that we have previously used the same plasmid, but with GFP or Cre in place of NPM-ALK or NPM-Ltk, to make transgenic lines, none of which show changed iridophore patterns (20, 21) ; similarly a kinase-dead version of the NPM-Ltk construct fails to generate supernumerary/ectopic iridophores (MN and RNK, unpub. data). We conclude that both the human oncogenic NPM-ALK and the NPM-Ltk proteins are able to drive neural crest cells to form iridophores, and can substitute for endogenous Ltk activity.
ALK inhibitor treatment inhibits NPM-ALK activity in vivo. These results
immediately suggested that the efficacy of candidate ALK inhibitors might be assessed in vivo by their addition to the bathing media of transient transgenic NPM-ALK embryos; effective compounds should inhibit both the NPM-ALK-dependent iridophores in ltk mutants and the NPM-ALK-dependent supernumerary/ectopic cells in wild-type embryos. To test this idea, we asked whether the new ALK inhibitor TAE684, known to be active against the NPM-ALK fusion in a mammalian context (13) , inhibited the effects of NPM-ALK expression in the zebrafish. We injected wild-type embryos with psox10:NPM-ALK, while control embryos were left uninjected. A lower dose of DNA was used in these experiments compared with those described before; this had the advantage of lowered embryonic mortality, whilst still retaining a readily detectable iridophore phenotype. A proportion of each set of embryos was treated with 2 µM TAE684, whereas the remainder were treated with 1% DMSO alone (Figure 3a) . At 3 days post fertilisation (dpf) the iridophore pattern of each embryo was assigned to one of three categories: i) normal iridophore pattern, a series of spots above dorsal neural tube, but lacking at this stage in dorsal head; ii) embryos with supernumerary or ectopic iridophores; and iii) embryos with decreased numbers of iridophores (Figure 3) .
Injection of psox10:NPM-ALK into wild-type embryos gave the expected supernumerary/ectopic iridophore phenotype, whereas plasmid injected, TAE684treated sibling embryos showed a striking reduction in this phenotype (Figure 3c,d; quantitated in e). We conclude that treatment of transient transgenic embryos with TAE684 provides effective inhibition of NPM-ALK-dependent iridophore development, providing proof-of-principle that our assay can be used to identify in vivo efficacy of ALK inhibitors.
To confirm this phenotype reflected a specific effect of ALK inhibition, rather than a coincidental off-target activity that also affects iridophores, we assessed the effects of Crizotinib in our assay. Crizotinib is an ALK/c-MET dual inhibitor with distinct pharmacophore and selectivity profile to TAE684. It has recently been demonstrated to be the most selective for ALK of a set of 72 kinase inhibitors profiled on >440 kinases in a competitive binding assay (22) . We repeated our test for inhibition of NPM-ALK expressing embryos using Crizotinib treatment and see that this treatment also reduces the number of embryos showing ectopic or supernumerary iridophores (Figure 3f) . We then tested whether this effect can be enhanced by treatment with a sub-optimal dose of a MEK inhibitor, PD0325901 [3] (Figure 1) , on the basis that MEK signalling is a major pathway downstream of receptor tyrosine kinase signalling (23) . Interestingly, a 500 nM dose of PD0325901 alone did not cause a pronounced inhibition of NPM-ALKdependent iridophores (Figure 3f) . In contrast, combined treatment of NPM-ALK injected fish with both PD0325901 and Crizotinib gives an enhanced inhibition of the ectopic/supernumerary cells (Figure 3f) . We conclude that two independent ALK inhibitors each inhibit the iridophore-inducing effect of NPM-ALK expression in zebrafish, strongly supporting the suggestion that ALK activity is the key factor driving these cells. In addition, our screen appears to be sensitised by treatment with low doses of MEK inhibitor.
TAE684 and Crizotinib-treatment inhibit Ltk activity in zebrafish. Given the sister kinase relationship of ALK and LTK, it is expected that even selective ALK inhibitors might also show activity against LTK. Crizotinib showed strong inhibition of c-Met and ALK out of a panel of 120 kinases, although it is not clear whether these included LTK (24) . In a cell proliferation assay TAE684 proved highly selective, being at least 100fold more effective against ALK than against 20 other kinases tested (13) , although the kinase panel tested did not include LTK. Specificity was higher in cellular assays than in direct enzymatic assays, and modelling suggested that part, but not all, of the specificity depended upon the bulk of the amino acid residue at position 258; we note that ALK and LTK in both human and zebrafish all have a conserved eu258 residue (Supp. Figure 1) . Biochemical profiling of both TAE684 and Crizotinib showed very similar strength of competitive binding of these compounds to both ALK and LTK as measured by Ambit Bioscience KinomeScan TM profiling, although the interaction profiles with other kinases in the panels tested were generally distinct (22, 25) 
Gray, pers. comm.). In addition, TAE684 shows a 50% inhibitory concentration (IC50) of 18 nM against LTK using Life Technologies Corporation, SelectScreen ® Kinase Profiling. Taken together, we considered that activity of TAE684 and Crizotinib against the zebrafish Ltk, in addition to ALK, in vivo was likely. Ltk loss-of-function mutants show graded degrees of iridophore number decrease (16, 26) . In our treatment of wildtype embryos with TAE684 we noticed that embryos frequently phenocopied ltk mutant embryos (Figure 3e) . Likewise, embryos treated with TAE684 and the NPM-ALK plasmid rarely showed the clean loss of the NPM-ALK-dependent iridophores alone, but instead usually showed a dramatic decrease in all iridophores (Figure 3d,e) .
Interestingly, the degree of iridophore decrease was dose-dependent (Supp. Figure   2a-d') , clearly phenocopying the allelic series of ltk mutant alleles (16) . Similar observations were made with Crizotinib-treated embryos (Supp. Figure 2e ; data not shown). Again, we saw sensitisation of this screen by low-dose treatment with the MEK inhibitor PD0325901 (Supp. Figure 2e) . We hypothesised that, in addition to inhibition of the NPM-ALK protein, both Crizotinib and TAE684 were also inhibiting endogenous Ltk activity.
To test more directly whether TAE684 might inhibit Ltk kinase activity in our in vivo context, we asked whether TAE684-treatment prevented the supernumerary/ectopic iridophores induced by injection of psox10:NPM-Ltk. As predicted, we saw that TAE684 inhibited formation of ectopic iridophores, and that this effect was often combined with loss of the endogenous cells (Figure 4) . We conclude that TAE684 shows significant in vivo activity as an Ltk inhibitor, and that this is highly likely for Crizotinib too.
Specificity of RTK inhibitor phenotypes in vivo. While both TAE684 and Crizotinib
show specific inhibition of exogenous ALK and endogenous and exogenous Ltk, the in vivo phenotypes are consistent with them not affecting other RTKs. For example, we never observed effects on other neural crest-derived pigment cells, including melanocytes, in TAE684 or Crizotinib-treated embryos. This is notable since mutations in the RTK Kit result in a prominent decrease in melanocyte numbers, a phenotype that is phenocopied by treatment of embryos with PDGFR/Kit tyrosine kinase inhibitor IV [5] ( Figure 1; Supp. Figure 3a-a'' ; (26, 27) . Thus, in vivo, TAE684 and Crizotinib appear to show no activity at these doses against Kit, consistent with the findings in cell proliferation studies (13) .
Conversely, we do not generally observe strong iridophore phenotypes with inhibitors directed against other RTKs. For example, treatment of wild-type embryos with the PDGFR/Kit inhibitor did not affect iridophores at doses that phenocopied the Kit mutant phenotype (data not shown). At higher doses, there were additional severe defects in eye and body morphology, consistent with off-target effects (Supp. Figure 3a', a'') .
Our results with the VEGFR inhibitor, Vatalanib (also known as PTK787/ZK222584) [4] (Figure 1) , were particularly interesting. Inhibition of VEGF-R using Vatalanib results in defective growth of blood vessels (28) . We were able to reproduce these findings using doses of even just 1.25 uM, but did not see consistent reduction in iridophores at this dose (Supp. Figure 3b) . This inhibitor is reported to show some activity against ALK (29) , and thus may also be expected to target LTK too, which likely explains why we do see an effect on iridophore numbers at higher doses (Supp. Figure 3b) .
In our dose-response experiment (Supp. Figure 2) we observed shortening of the body axis at 6 µM, and embryonic lethality at 10 µM, suggesting that higher doses induced substantial off-target effects. Nevertheless, the specific inhibition of iridophore phenotypes occurred cleanly at lower doses. We conclude that our iridophore assay is specific to ALK and Ltk activity, and effects of drug treatment on other targets often result in detectable, but distinct, phenotypes.
Conclusion
We have developed the zebrafish system as a simple and effective assay for ALK inhibition in vivo. We use iridophore number as a direct functional readout of oncogenic ALK activity, allowing a simple visual screen for chemical inhibitors of that activity. We show that inhibition of oncogenic ALK can be distinguished from effects on even the very closely-related Ltk (comparing supernumerary versus endogenous iridophore numbers).
We also show that Ltk iridophore activity is sensitive to TAE684 (and likely Crizotinib), providing a parallel assay to assess Ltk activity based on screening wildtype embryos for reduction of iridophores. Such a screen may be useful in the identification of drug-leads against LTK, which may have application in treatment of systemic lupus erythematosis (30) . Such a screen might also identify additional ALK inhibitors, however the ALK inhibitor assay described here has the advantages of directly assessing inhibition of the human oncogenic protein and of being straightforward to adapt to other oncogenic ALK variants, including activating point mutations such as are found in Inflammatory myoblastic tumour and neuroblastoma (9, 10, 15) .
We note also that our data indicates that use of low doses of MEK inhibitor PD0325901 provides a sensitised ALK inhibitor screen which may be advantageous when searching for novel lead compounds.
One limitation of the current assay is the mosaicism due to the transient transgenic nature of the embryos used. Further refinement of our assay using conditionally-expressing transgenic lines (31) to allow us to ensure that all embryos express the transgene in all neural crest cells without constitutive lethality would substantially improve assay efficiency, and would facilitate the screening of large numbers of molecules. Iridophores are auto-fluorescent and combined with recent advances in high-throughput microscopy (32) , our assay can be readily adapted to an automated, quantitative assessment of in vivo ALK kinase activity. Zebrafish are increasingly popular for medium-large scale drug screens, where the embryos' small size, optical clarity, external development in aqueous medium, and ease of genetic manipulation to make transgenic reporter lines, make them ideally suited (33, 34) .
In summary, we believe that our assay is unique in combining several powerful features in an in vivo context including: 1) quantitative readout of functional activity of ALK mutations; 2) sensitive detection of off-target effects; 3) potential for automation for high-throughput; 4) suitability for screening for genetic and chemical suppressor mutations, and for 5) testing combination therapies on resistant ALK mutations. Given the significant animal welfare and cost advantages of using zebrafish embryos, our assay system offers substantial opportunities for early assessment of in vivo efficacy and specificity of lead molecules in the drug development pipeline. These assays might even be further adapted for other RTKs, thus offering even greater utility as a drug development tool.
Methods
Full details of methods used are provided in the supplementary material that accompanies this paper online.
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